See NewAmsterdam Pharma Company NV's analyst price targets ($51) vs the current share price.
Get informed when a big investor buys or sells
+ Follow$25.4
3 analysts in the last 4 months
High: $58 | Low: $45
No recommendations in the last 4 months.
NewAmsterdam Pharma Company NV (NAMS) currently reports a target price of $51. Use the charts on this page to explore NewAmsterdam Pharma Company NV's target price history and peer comparisons.
Analysts' average 12-month price target for NewAmsterdam Pharma Company NV is $51, about 102.1% upside from the current share price of $25.4. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.
Start with the current target price of $51, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.